Study identifies optimal treatment options for advanced hepatocellular carcinoma

A comprehensive study involving 23 randomized controlled trials has shed light on optimal treatment options for advanced hepatocellular carcinoma (HCC). In the first-line treatment, the combination of a PD-1 inhibitor with bevacizumab and the combination of PD-1 inhibitors with TKIs or bevacizumab demonstrated significant efficacy in extending overall survival and...